GBI生物制造公司任命钱德拉·凯利为首席商务官

PLANTATION, Fla.

佛罗里达州种植园

,

，

May 27, 2026

2026年5月27日

/PRNewswire/ -- GBI Biomanufacturing, Inc., (GBI) a leading biologics Contract Development and Manufacturing Organization (CDMO), today announced the appointment of

/PRNewswire/ -- GBI生物制造公司（GBI），一家领先的生物制品合同开发和制造组织（CDMO），今天宣布任命

Chandra Kelley

钱德拉·凯利

as

作为

Chief Business Officer (CBO)

首席商务官 (CBO)

. In this role, Kelley will lead the company's commercial strategy, business development organization, client engagement initiatives, and long-term growth planning as the company continues to expand its capabilities and market presence.

在此职位上，凯利将领导公司的商业战略、业务发展组织、客户参与计划以及长期增长规划，因为公司将继续扩大其能力和市场影响力。

Continue Reading

继续阅读

Chandra L. Kelley

钱德拉·L·凯利

Kelley brings more than 25 years of experience in the biotechnology and biopharmaceutical industry, with a proven track record of driving commercial growth, building strategic partnerships, and scaling customer-focused sales organizations across large molecule development and manufacturing services.

凯利在生物技术和生物制药行业拥有超过25年的经验，有着推动商业增长、建立战略合作伙伴关系以及扩大以客户为中心的销售组织的可靠记录，涵盖大分子开发和制造服务领域。

Prior to joining GBI, she held senior commercial development roles at KBI Biopharma, Pfanstiehl, and SAFC..

在加入GBI之前，她曾在KBI生物制药公司、Pfanstiehl公司和SAFC公司担任高级商务发展职务。

'GBI Biomanufacturing is entering an exciting new phase of growth and capability expansion,' said Jesse McCool, President of GBI Biomanufacturing. 'Chandra brings the client and market insights needed to deepen the way we support our early-stage antibody and ADC projects. Her experience structuring integrated and phase-appropriate work packages for rapid early phase supply aligns exceptionally well with GBI's latest solutions in the mAb and bioconjugation space.'.

“GBI生物制造正在进入一个令人兴奋的增长和能力扩展的新阶段，”GBI生物制造总裁Jesse McCool表示。“Chandra带来了深化我们对早期抗体和ADC项目支持方式所需的客户和市场洞察。她在构建用于快速早期供应的综合且适合阶段的工作包方面的经验，与GBI在单克隆抗体和生物偶联领域的最新解决方案高度契合。”

As CBO, Kelley will focus on expanding the company's customer base, enhancing strategic partnerships, improving proposal and project evaluation processes, and aligning commercial execution with operational capabilities to support sustainable growth.

作为首席商务官，凯利将专注于扩大公司的客户群、加强战略合作伙伴关系、改进提案和项目评估流程，并将商业执行与运营能力相结合，以支持可持续增长。

'I'm excited to join GBI at such a dynamic stage of growth,' said Kelley. 'GBI recently built an impressive expansion in South Florida that adds commercial-scale production capacity for complex biologics, complementing the company's long-standing expertise in mammalian-based production of recombinant proteins.

“我很高兴在这个充满活力的增长阶段加入GBI，”凯利说道。“GBI最近在南佛罗里达州进行了令人印象深刻的扩展，增加了复杂生物制品的商业化生产能力，这与公司长期以来在基于哺乳动物的重组蛋白生产方面的专业知识相辅相成。”

What stands out most is the organization's commitment to scientific excellence, operational flexibility, and their unmatched customer service. I look forward to partnering with the team to further strengthen GBI's position as a trusted CDMO partner supporting clients from development through commercialization.'.

最突出的是该组织对科学卓越、运营灵活性以及无与伦比的客户服务的承诺。我期待与团队合作，进一步巩固GBI作为值得信赖的CDMO合作伙伴的地位，支持客户从开发到商业化的过程。

GBI is a fully integrated biologics development and manufacturing partner with more than 30 years of operating experience in South Florida. The company supports a broad range of biologic modalities — including protein biologics, bioconjugates, exosomes, and stem cell therapies — within a unified cGMP and regulatory framework.

GBI是一家拥有30多年南佛罗里达运营经验的全方位生物制品开发和生产合作伙伴。公司在统一的cGMP和监管框架下，支持广泛的生物制品模式，包括蛋白质生物制品、生物偶联物、外泌体和干细胞疗法。

This integrated approach enables sponsors to advance programs seamlessly from early development through commercialization with a single CDMO partner..

这种综合方法使赞助商能够通过单一的CDMO合作伙伴无缝推进项目，从早期开发到商业化。

From cell line development (CLD) through drug product (DP) fill and finish, GBI supports GMP manufacturing across multiple single-use bioreactor (SUB) scales, including 50 L, 200 L, 500 L, and 2000 L fed-batch systems, as well as 50 L and 500 L perfusion platforms. Its in-house semi-automated and automated fill lines enable early-stage drug product manufacturing under the same roof as drug substance production, creating an efficient .

从细胞系开发 (CLD) 到药物产品 (DP) 的灌装和完成，GBI 支持多个一次性生物反应器 (SUB) 规模的 GMP 生产，包括 50 L、200 L、500 L 和 2000 L 的补料分批系统，以及 50 L 和 500 L 的灌流平台。其内部半自动化和自动化灌装线能够在同一屋檐下进行早期阶段的药物产品生产与药物物质生产，从而创造高效流程。

Single-Source Solution™

单一来源解决方案™

workflow. For later-phase and commercial-scale needs beyond Phase 1, GBI also leverages strategic manufacturing partnerships to support continued program expansion and commercialization readiness.

工作流程。对于第一阶段之后的后期阶段和商业规模需求，GBI还利用战略制造合作伙伴关系来支持项目的持续扩展和商业化准备。

About GBI

关于GBI

GBI is a Florida-based, full-service biopharmaceutical CDMO focused on reducing manufacturing risk for developers of complex biologic therapies. Over 30 years, the company has supported more than 400 large-molecule projects and over 50 regulatory filings, demonstrating proven, resilient platforms and service capabilities.

GBI是一家总部位于佛罗里达州的全方位服务生物制药合同开发与生产组织（CDMO），专注于为复杂的生物疗法开发者降低生产风险。在过去的30年中，该公司已支持了400多个大分子项目和50多项监管申报，展示了其经过验证的、灵活的平台和服务能力。

With comprehensive process development, advanced manufacturing infrastructure, strategic sub-contractor and supplier networks, and dedicated project management, GBI provides reliable, end-to-end CDMO partnership for biologics programs. Their approach combines scientific expertise and practical innovation to develop efficient solutions tailored to each biologics project, regardless of complexity..

通过全面的工艺开发、先进的制造基础设施、战略分包商和供应商网络以及专门的项目管理，GBI 为生物制品项目提供可靠的端到端 CDMO 合作伙伴关系。他们的方法结合了科学专业知识和实用创新，为每个生物制品项目开发高效的解决方案，无论其复杂性如何。

Media Contact

媒体联系人

Yaslin Alicea–Hidrovo

雅斯林·阿利塞亚-伊德罗沃

Business Development & Marketing Specialist

商务拓展与营销专员

GBI Biomanufacturing

GBI 生物制造

1850 NW 69th Ave,

1850 NW 69th Ave,

Plantation FL 33313

佛罗里达州普兰泰申 33313

United States

美国

Tel: +1 (954) 256-0585

电话：+1 (954) 256-0585

Email:

电子邮件：

[email protected]

电子邮件地址

SOURCE GBI Biomanufacturing

源GBI生物制造

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示